Zydus Cadila Approval from US FDA - Angel Broking

Mr. Yash Gupta - Equity Research Associate, Angel Broking Ltd

"Zydus Cadila has received final approval from the USFDA for market Cisatracurium Besylate Injection USP (US RLD: Nimbex ®) in the strength of 20 mg (base)/10 mL (2 mg/mL) Multiple-Dose Vial. Cisatracurium Besylate is a nondepolarizing skeletal neuromuscular blocker for intravenous administration. It is an adjunct to general anaesthesia to facilitate tracheal intubation in adults and in paediatric patients 1 month to 12 years of age and to provide skeletal muscle relaxation in adults during surgical procedures or during mechanical ventilation in the ICU. This is positive news for Zydus Cadila."

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.381.95 as compared to the previous close of Rs. 378.15. The total number of shares traded during the day was 155058 in over 2718 trades.

The stock hit an intraday high of Rs. 383.7 and intraday low of 373.5. The net turnover during the day was Rs. 58869902.

Source : Equity Bulls

Keywords